1. Home
2. Finances
3. Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Image

Date de parution

2024/06/26

PDF du document

Crossject_PR_RAMPART_26062024_EN.pdf241.9 KB